a CARD (caspase recruitment domain) protein that belongs to the membrane-associated guanylate kinase (MAGUK) family. MAGUK proteins function as molecular scaffolds for the assembly of multiprotein complexes at specialized regions of the plasma membrane. Contains an N-terminal CARD domain, a central coiled-coil domain, and a C-terminal region containing a PDZ, an SH3, and a GUK. Its CARD domain associates with the CARD domain of BCL10. BCL10 activates NF-kappaB through the IkappaB kinase complex in response to upstream stimuli. Apparently activates NF-kappaB and induce the phosphorylation of BCL10. Detected in adult peripheral blood leukocytes, thymus, spleen and liver. Also found in promyelocytic leukemia HL-60 cells, chronic myelogenous leukemia K562 cells, Burkitt's lymphoma Raji cells and colorectal adenocarcinoma SW480 cells. Note: This description may include information from UniProtKB.
Molecular Function: CARD domain binding; guanylate kinase activity; protein binding
Biological Process: activation of NF-kappaB transcription factor; GDP metabolic process; GMP metabolic process; innate immune response; positive regulation of B cell proliferation; positive regulation of cytokine production; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of interleukin-2 biosynthetic process; positive regulation of T cell proliferation; regulation of apoptosis; regulation of B cell differentiation; regulation of T cell differentiation; stimulatory C-type lectin receptor signaling pathway; T cell costimulation; T cell receptor signaling pathway; thymic T cell selection
Alt. Names/Synonyms: bcl10-interacting maguk protein 3; BIMP3; CAR11; CARD-containing MAGUK protein 1; card-maguk protein 1; CARD11; Carma 1; CARMA1; caspase recruitment domain family, member 11; Caspase recruitment domain-containing protein 11; MGC133069
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.